Semi‐Mechanistic <scp>PK</scp> / <scp>PD</scp> Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With Myelofibrosis
/L with ruxolitinib minimized thrombocytopenia risk while maintaining efficacy. Dose reductions of 25 mg for the 100 mg start and 50 mg (plus 25 mg if needed) for the 200 mg start optimized the benefit-risk balance.
Authors
- RM Menon
- Sven Mensing (ORCID: https://orcid.org/0000-0002-9434-647X)
- Carla Biesdorf (ORCID: https://orcid.org/0000-0002-6879-6557)
- Aline Goebel (ORCID: https://orcid.org/0000-0001-5059-9427)
- Benjamin Engelhardt
- Akshanth R. Polepally (ORCID: https://orcid.org/0000-0002-5938-6062)
- Maulik Patel
- Jalaja Potluri
Institutions
- Ludwigshafen University of Business and Society (DE)
- AbbVie (United States) (US)
Publication Details
- Journal
- CPT Pharmacometrics & Systems Pharmacology
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1002/psp4.70260
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AbbVie